BioSpace News Archive

(“IR-MED or the “Company”) (OTCQB:IRME), an innovative development stage medical device company that utilizes Infra-Red light spectroscopy (IR) combined with Artificial Intelligence (AI) technologies to develop non-invasive detection devices, announced that its wholly-owned subsidiary IR-Med Ltd. has signed a study agreement with Beit Rivka, a Large Geriatric Hospital in Israel associated with Clalit, the largest Health Insurance Fund in Israel.

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization in Europe for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for use as primary vaccination in people from 18 to 50 years of age.

Evergreen Nephrology is announcing a joint venture with Dallas Nephrology Associates, one of the nation’s largest teams of kidney specialists, and a leader and trusted source for kidney care in the Dallas-Fort Worth area for over 50 years.

NeuPath Health Inc., owner and operator of a network of clinics delivering category-leading chronic pain treatment, announced the voting results from its Annual General and Special Meeting of Shareholders held on June 22, 2022 and the issuance of stock options and restricted share units.

TRIANA Biomedicines, Inc. announced the addition of Robert A. Copeland, PhD, and Adrian M. Senderowicz, MD to its Scientific Advisory Board.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), today announced that the Italian Medicines Agency, or Agenzia Italiana del Farmaco (AIFA), has authorized Alterity to conduct its Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.

Oncopeptides AB announces that the European Medicines Agency’s Committee for Medicinal Products for Human Use, has unanimously adopted a positive opinion recommending a full marketing authorization approval of Pepaxti® in EU.

AMRA Medical will present the results of their recent study using magnetic resonance imaging (MRI) to measure muscle composition changes in individuals with metabolic disorders at the 2022 SCWD Conference.

ClorDiSys is proud to have been a part of the 2022 Kilmer Conference held in Athens, Greece.